Vision, Mission and Values of Fermenta Biotech

Vision, Mission and Values

Vision: To create a system and nurture it to reach a state of functioning, enabling it to acquire a state of timeless stability and growth.

Mission: To produce high-quality niche products, used in every line of pharmaceutical, food and fine chemical manufacture, through innovative and concentrated research efforts, thus becoming the most preferred eco-friendly solutions provider in bio-catalysis and pharmaceuticals.

Core values: Discipline, Honesty, Mutual Respect, Perseverance & Result-orientation

History and Milestones

History

Fermenta Biotech Limited (earlier known as DIL Ltd.) is a well-respected public listed company. It has built a stellar reputation for itself in the arenas of pharmaceuticals, biotechnology, environmental solutions and real estate.

The conglomerate of today certainly had quite humble beginnings. The late Dr. Datla Venkata Krishnam Raju or Dr. DVK Raju as he was fondly called; was a legend of extraordinary caliber, a man of vision and a pioneer of the Indian drug industry.

Born in a village in Andhra Pradesh, Dr. DVK Raju was a self-made man. Armed with a Doctorate in Pharmaceutical Chemistry from London School of Pharmacy, entrepreneurial acumen and a nationalistic outlook, he returned to India in 1948 to start an entrepreneurial venture.

On 1 May 1951, Dr. Raju incorporated ‘International Franchises Private Limited’, a company specializing in the manufacture of pharmaceutical products on behalf of multinational companies.

Read more
Milestones

1951

  • Incorporated International Franchises Private Limited, a company specializing in toll manufacturing of pharmaceutical products.

1959

  • Set up a manufacturing facility in Thane to develop its own pharmaceutical range of products

1963

  • Entered into a joint venture with Phillips Duphar and Crookes Laboratory UK.
  • Name changed to Crookes Interfran Ltd (CIL).

1967

  • Commercial manufacturing of Vitamin D commenced for the first time
  • Launch of “Crocin” and “Lacto Calamine”

1971

  • Phillips Duphar acquired shares of CIL from Crookes Lab UK and changed the name to Duphar Interfran Ltd.

1977

  • The Company’s securities got listed on the Bombay Stock Exchange

1980

  • Phillips Duphar SV was taken over by Solvay and Solvay became the JV Partner.

1985

  • Dr. DVK Raju stepped down from active management; his son Mr. Datla Vasant Kumar took over as Managing Director

1986

  • Founded Fermenta Biotech Ltd (FBL) with a manufacturing facility located in Kullu.

1996

  • Divested OTC brands Crocin & Lacto Calamine.

2002

  • Demerged the Pharma business that was sold to Solvay.

2003

  • Expanded the manufacturing capacity with Vitamin D3 and other products like Phenyramidol at Kullu.
  • Changed the name of the Company to DIL Ltd.

2005

  • Mr. Krishna Datla, took over as Managing Director (after the untimely demise of his father Mr. Datla Vasant Kumar).

2006

  • Introduced Dilbeads, oxirane polymer beads , for enzyme immobilisation.
  • Launched a PGA catalyst blend (Fermase PAR 450) for cephalosporin intermediates

2007

  • Scaled capacities to enter export markets.
  • Launched Dimethicone powder
  • Received Kosher certification for Vitamin D3

2008

  • Received Halal certification for Vitamin D3

2009

  • Launched novel penicillin G acylase (NPGA) for β-lactam antibiotic synthesis (e.g. Amoxicillin)
  • Obtained CEP certification for Vitamin D3 from EDQM for its Kullu plant
  • Started exporting Vitamin D3
  • Introduced Phenyramidol formulations in India

2011

  • Commenced the second plant for the manufacture of Vitamin D3 at Dahej SEZ, Gujarat.
  • Ventured into animal feed and oil supplements of Vitamin D3.
  • Applied for Canadian DMF and US DMF.

2012

  • Underwent US FDA inspection for dietary supplements at Kullu.
  • Commercialised novel penicillin G acylase (NPGA) Fermase PS 150 for major global customers.
  • Launched new and improved penicillin G acylase catalyst – Fermase PA 850.
  • Augmented Vitamin D3 resin manufacturing capacity in Dahej.
  • Entered into the real estate venture called Thane One.

2014

  • Initiated the commercial production of Vitamin D3 100 CWD to cater to the food and dietary nutraceutical supplements market.
  • Launched Phenyramidol formulations in Africa.

2016

  • Enhanced Vitamin D3 capacity at its new plant at Dahej.
  • Launched new version of Vitamin D3 500 feed grade.

2017

  • Received CEP from EDQM for the Dahej facility for Vitamin D.
  • Received FSSC 22000 and BRC Food Safety Approvals for both the plants for Vitamin D manufacture.

2019

  • Executed a 99-year lease agreement for the acquisition of land aggregating about 40,000sq. m. from the Gujarat Industrial Development Corporation (GIDC) in Ankleshwar, Sayakha, for expansion and new projects manufacture.
  • The National Company Law Tribunal, Bench at Mumbai, has approved the Scheme of Amalgamation ('Scheme') between the Transferee company i.e. DIL Limited (DIL) and the Transferor company i.e. Fermenta Biotech Limited (FBL). The Scheme has become effective from September 26, 2019.
  • Post-merger, the name of the merged company is changed from DIL Limited to Fermenta Biotech Limited as per the certificate of incorporation pursuant to name change dated October 17, 2019 issued by the Registrar of Companies, Mumbai
  • Set up a wholly-owned subsidiary, Fermenta Biotech GmbH, in Hamburg, Germany, to provide support for local toll manufacturing projects in addition to reinforcing its endeavor to achieve customer proximity.

2020

  • Launched fish oil cholesterol for aquaculture applications
  • Set up a wholly owned international subsidiary called Fermenta Biotech USA LLC, in USA
  • Fermenta Biotech USA LLC acquired a majority stake in US-based vitamins player AGD Nutrition (renamed Fermenta USA LLC)

2021

  • Developed and filed patent application(s) for enzymatic synthesis of Molnupiravir, a COVID-19 drug
  • Launched Vitamin AD2 premix for oil fortification

2022

  • Exclusively licensed its enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Limited, a step-down subsidiary of Dr Reddy’s Laboratories Limited
  • Signed a binding term sheet with Mextech Property Developers LLP (incorporated by promoters of Nandivardhan Group and RRC Ventures Pvt. Ltd.) for the development of its land parcel in Thane

2023

  • Inaugurated Customized Premix manufacturing plant in Kullu, Himachal Pradesh
  • Commissioned Fortified Rice Kernel manufacturing facility in Andhra Pradesh

Members of the Board

Mr.pradeep

Mr. Pradeep Chandan

Chairman (Non-Executive and Independent)

Mr. Pradeep M. Chandan is a graduate in Commerce & Law from Mumbai University

Ms.Rajeshwari-Datla

Ms. Rajeshwari Datla

Non-Executive Director

Ms. Rajeshwari Datla has rich experience in the Pharmaceutical Industry. Ms. Datla joined the Board

Ms. Datla is a Director in Dupen Laboratories Private Limited as well. What’s more, Ms. Datla is a member of Audit Committee of the company.
Pramod V3

Mr. Pramod Kasat

Independent Director

Mr. Kasat, Managing Director of Intellecap Advisory Services, has vast experience in Investment Banking, Capital Markets and Global Market Solutions.

Mr.Krishna-Datla

Mr. Krishna Datla

Executive Vice-Chairman

A Commerce Graduate from Mumbai University, Mr. Krishna Datla believes in progressive

Mr.Satish-Varma

Mr. Satish Varma

Executive Director

Mr. Satish Varma joined FBL group (Formerly known as DIL group) as the Executive Assistant

Ms.Anupama-Datla-Desai

Ms. Anupama Datla Desai

Executive Director

Ms. Anupama Datla Desai has been appointed as an additional director

Ms. Rajashri Ojha

Ms. Rajashri Ojha

Non-Executive Independent Director

Ms. Rajashri Ojha has over 2.8 decades of experience in pharmaceutical industry

Mr.Prashant-Nagre

Mr. Prashant Nagre

Managing Director

Prashant Nagre is Managing Director of the company. Nearly three decades in the pharmaceuticals industry.

Key Managerial Personnel

Mr.Sumesh-Gandhi

Mr. Sumesh Gandhi

Group Chief Financial Officer

Sumesh is a qualified Chartered Accountant coupled with Masters in Finance. He has over 24 years of experience

Contact for Investor's Grievance Redressal

Compliance Officer & Nodal Officer

Mr. Varadvinayak Khambete

Tel: +91 22 6798 0888

Fax: +91 22 6798 0888

Email: varadvinayak.khambete@fermentabiotech.com

R&T Agent details

Link Intime India Private Limited

C 101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400 083, Maharashtra, India

Tel: + 91 22 49186000

Fax: + 91 22 49186060

Email:rnt.helpdesk@linkintime.co.in

Awards and Recognitions

India-Pharma-Awards-2018

India Pharma Awards 2018

Hindustan-Times-Thane-Ratna-Award-2019

Hindustan Times Thane Ratna Award 2019

Business-Excellence-Awards-2019

World HRD Congress 2018

Pride-of-Maharashtra-Award-2018

Pride of Maharashtra Award 2018

World-HRD-Congress-2018

Business Excellence Awards 2019

HT-Thane-Ratna-Trophy

Hindustan Times Thane Ratna Award 2020

Turnaround-Strategy-2020

Chief Strategy Officer Summit & Awards 2020

World-HRD-Congress

Business Leader of the Year Awards 2020

aw6

Indian Green Building Council Award

Fbl-Images

India Pharma Awards 2021

Fbl-Images-(Slot-2)

Pride of Maharashtra Award 2021

Excellence in pharma supply chain award 2023

Excellence in Pharma Supply Chain Award 2023

Our Locations

Registered office, Thane - Fermenta Biotech

Registered office, Thane

Fermenta Biotech R&D, Thane

R&D, Thane

Manufacturing Facility, Kullu - Fermenta Biotech

Manufacturing Facility, Kullu

 Manufacturing Facility, Dahej - Fermenta Biotech

Manufacturing Facility, Dahej

Proposed Manufacturing Facility, Saykha - Fermenta Biotech

Manufacturing Facility, Andhra Pradesh

Proposed Manufacturing Facility, Saykha - Fermenta Biotech

Proposed Manufacturing Facility, Saykha

Fermenta Biotech GmbH, Germany

Fermenta Biotech GmbH, Germany

Proposed Manufacturing Facility, Saykha - Fermenta Biotech

Fermenta USA LLC

Our subsidiaries: Click here

images